To discover, research and develop programs leveraging Secarna’s antisense oligonucleotide expertise with Evotec’s discovery and development capabilities.
Market estimated to grow at CAGR of 20% from 2021 to 2028 due to an exponential rise in clinical pipeline along with rising number of regulatory approvals.